Vetter Pharma

Vetter Pharma, a German company in the Surgical and Medical Instrument Manufacturing industry, has disclosed its carbon emissions and climate commitments.

In 2025, Vetter Pharma reported Scope 1 emissions of approximately 18,779,000 kg CO2e and Scope 3 emissions of about 496,085,000 kg CO2e. This includes Scope 1 emissions from stationary combustion (17,031,440 kg CO2e), mobile combustion (415,810 kg CO2e), and fugitive emissions (477,190 kg CO2e). Notable Scope 3 categories for 2025 include purchased goods and services (269,420,530 kg CO2e), capital goods (175,841,290 kg CO2e), and upstream transportation and distribution (18,940,340 kg CO2e).

Looking back, in 2024, the company's Scope 1 emissions were approximately 16,986,000 kg CO2e, and Scope 3 emissions were around 393,795,000 kg CO2e. In 2023, Scope 1 emissions were about 17,852,000 kg CO2e, and Scope 3 emissions were approximately 271,087,000 kg CO2e. For 2022, reported Scope 1 emissions were around 18,000,000 kg CO2e, with Scope 3 emissions of about 408,611,000 kg CO2e. In 2021, Vetter Pharma recorded Scope 1 emissions of approximately 19,683,000 kg CO2e and Scope 3 emissions of about 217,431,000 kg CO2e.

Vetter Pharma has set ambitious climate targets. The company is committed to achieving net-zero emissions by 2050. For near-term reductions, Vetter Pharma-Fertigung GmbH & Co. KG has a Science Based Target initiative (SBTi) validated commitment to reduce absolute Scope 1 and 2 greenhouse gas emissions by 58.8% by 2034, against a 2021 base year. Additionally, they aim for 80% of their suppliers (by spend, covering purchased goods and services, capital goods, and upstream transportation and distribution) to have science-based targets by 2029.